DK2383284T3 - Peptidsekvenser og sammensætninger - Google Patents

Peptidsekvenser og sammensætninger Download PDF

Info

Publication number
DK2383284T3
DK2383284T3 DK11157382.0T DK11157382T DK2383284T3 DK 2383284 T3 DK2383284 T3 DK 2383284T3 DK 11157382 T DK11157382 T DK 11157382T DK 2383284 T3 DK2383284 T3 DK 2383284T3
Authority
DK
Denmark
Prior art keywords
drb1
polypeptide
seq
influenza
hla
Prior art date
Application number
DK11157382.0T
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparras-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2383284(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602416A external-priority patent/GB0602416D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Application granted granted Critical
Publication of DK2383284T3 publication Critical patent/DK2383284T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (13)

1. Polypeptid, der består af ikke mere end 100 aminosyrer, hvilket polypeptid omfatter én eller flere sekvenser af SEQ ID NO: 3 og/eller én eller flere sekvenser, der har mindst 85 % homologi med den 21. aminosyresekvens ifølge SEQ ID NO: 3: SEQ ID NO: 3 DLIFLARSALILRGSVAHKSC hvor polypeptidet er immunogent i et hvirveldyr, der udtrykker en større histokompatibilitetskompleks-(MHC)-allel, og hvor polypeptidet er immunogent over for en flerhed af influenzavirusstammer.
2. Polypeptid ifølge krav 1, hvilket polypeptid endvidere omfatter: én eller flere sekvenser, der har mindst 85 % homologi med den fulde aminosyresekvens af en hvilket som helst af SEQ ID NO: 1, 2 og 4-6: SEQ ID NO: 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID NO: 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID NO: 4 PGIADIEDLTLLARSMVWRP SEQ ID NO: 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID NO: 6 IIGILHLILWILDRLFFKCIYRLF
3. Polypeptid ifølge et hvilket som helst af de foregående krav, hvilket polypeptid omfatter en cytotoksisk T-lymfocyt- (CTL) epitop, og/eller er immunogent til en epitop i sekvensen SEQ ID NO: 3, og/eller endvidere omfatter én eller flere sekvenser fra et influenzavirusprotein, fortrinsvis hvor når polypeptidet er mindst 85 % homologt med den 21. aminosyresekvens ifølge SEQ ID NO: 3, proteinet er et influenza NP-protein, og/eller hvor homologien er 100 %, og/eller hvor polypeptidet består af ikke mere end 50 aminosyrerester.
4. Polypeptidsammensætning, der omfatter to eller flere polypeptider som defineret ifølge et hvilket som helst af de foregående krav.
5. Polypeptidsammensætning ifølge krav 4, der endvidere omfatter én eller flere sekvenser, der består af ikke mere end 100 aminosyrer, hvilke sekvenser omfatter: en sekvens, der har mindst 85 % homologi med den fulde aminosyresekvens ifølge en hvilket som helst af SEQ ID NO: 1, 2 og 4-6: SEQ ID NO: 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID NO: 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID NO: 4 PGIADIEDLTLLARSMVWRP SEQ ID NO: 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID NO: 6 IIGILHLILWILDRLFFKCIYRLF fortrinsvis hvori polypeptider med sekvenserne SEQ ID NO: 1, 3, 4 og 6 alle er til stede, og fortrinsvis hvori polypeptider med sekvenserne SEQ ID NO: 1-6 alle er til stede.
6. Polypeptid, eller polypeptidsammensætning, som defineret ifølge et hvilket som helst af de foregående krav til anvendelse i medicin.
7. Fremgangsmåde til fremstilling af et polypeptid som defineret ifølge et hvilket som helst af de foregående krav, hvilken fremgangsmåde omfatter kombinering af to eller flere sekvenser for at danne polypeptidet.
8. Polypeptidkonstrukt, der består af ikke mere end 100 aminosyrer, hvilket konstrukt omfatter et polypeptid som defineret ifølge et hvilket som helst af de foregående krav blandet med en bærer, hvor bæreren er et hjælpestof og/eller en excipiens.
9. Fremgangsmåde til fremstilling af et polypeptidkonstrukt som defineret ifølge krav 8, hvilken fremgangsmåde omfatter kombinering af to eller flere sekvenser og/eller et polypeptid og blanding med bæreren.
10. Medikament eller vaccinesammensætning mod influenza, der omfatter et polypeptid, eller en polypeptidsammensætning som defineret ifølge et hvilket som helst af de foregående krav, og eventuelt en/et passende excipiens og/eller hjælpestof.
11. Fremgangsmåde til fremstilling af et medikament eller vaccinesammensætning som defineret ifølge krav 10, hvilken fremgangsmåde omfatter blanding af et polypeptid, eller en polypeptidsammensætning som defineret ifølge et hvilket som helst af kravene 1-6 med en/et passende excipiens og/eller hjælpestof.
12. Anvendelse af et polypeptid, en polypeptidsammensætning, et polypeptidkonstrukt eller et medikament eller vaccinesammensætning som defineret ifølge et hvilket som helst af de foregående krav i fremstilling af et medikament eller en vaccine, der er effektiv(t) til behandling eller forebyggelse af influenza.
13. Polypeptid, polypeptidkonstrukt, fremgangsmåde, medikament, vaccine eller anvendelse ifølge et hvilket som helst af de foregående krav, hvor influenzaen er en influenza A-stamme eller influenzaen er en influenza B-stamme.
DK11157382.0T 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger DK2383284T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602416A GB0602416D0 (en) 2006-02-07 2006-02-07 Peptide sequences and compositions
GBGB0613977.8A GB0613977D0 (en) 2006-02-07 2006-07-13 Peptide sequences and compositions
EP07712678A EP1991563B1 (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
DK2383284T3 true DK2383284T3 (da) 2016-12-12

Family

ID=38109631

Family Applications (4)

Application Number Title Priority Date Filing Date
DK17180723.3T DK3263589T5 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger
DK11157382.0T DK2383284T3 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger
DK11157383.8T DK2383285T3 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger
DK07712678.7T DK1991563T3 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17180723.3T DK3263589T5 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11157383.8T DK2383285T3 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger
DK07712678.7T DK1991563T3 (da) 2006-02-07 2007-02-05 Peptidsekvenser og sammensætninger

Country Status (23)

Country Link
US (10) US8475802B2 (da)
EP (6) EP3620463A1 (da)
JP (1) JP5603551B2 (da)
KR (1) KR20080100441A (da)
CN (3) CN102807608B (da)
AP (1) AP2646A (da)
AT (1) ATE534660T1 (da)
AU (1) AU2007213562A1 (da)
BR (1) BRPI0707543B8 (da)
CA (1) CA2641602A1 (da)
DK (4) DK3263589T5 (da)
EA (1) EA017387B1 (da)
ES (4) ES2790730T3 (da)
GB (1) GB0613977D0 (da)
HK (1) HK1249115A1 (da)
IL (2) IL193232A (da)
MX (1) MX2008010113A (da)
NO (1) NO20083416L (da)
NZ (1) NZ570553A (da)
PL (4) PL2383285T3 (da)
PT (1) PT1991563E (da)
SG (1) SG169392A1 (da)
WO (1) WO2007091030A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
PT2173376E (pt) * 2007-08-02 2015-07-30 Biondvax Pharmaceuticals Ltd Vacinas de influenza multiepitópicas multiméricas
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2195466T3 (da) 2007-10-01 2013-01-14 Longhorn Vaccines & Diagnostics Llc Fremgangsmåde til opbevaring af biologiske prøver
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2072529A1 (en) * 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
CA2970211A1 (en) * 2014-12-10 2016-06-16 Vaxsia Biomedical Inc. Novel protein structure produced by effective antibody used for immunization
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) * 2015-06-30 2017-01-11 中国科学院上海巴斯德研究所 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
KR101888751B1 (ko) * 2016-09-22 2018-09-21 이화여자대학교 산학협력단 인플루엔자 b 백신
MX2019007924A (es) * 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
JP2023534839A (ja) * 2020-07-21 2023-08-14 フルゲン， インコーポレイテッド インフルエンザウイルスバックボーン

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981782A (en) 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
NZ255683A (en) * 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) * 1997-02-14 2007-09-11 At&T Corp. Non-linear quantizer for video coding
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
WO2002026252A1 (fr) 2000-08-10 2002-04-04 Tsinghua University Vaccin contre le virus de la grippe et son procede de preparation
ES2327103T3 (es) * 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050013826A1 (en) * 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US7262045B2 (en) * 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
JP2006519775A (ja) 2003-03-07 2006-08-31 メルク　エンド　カムパニー　インコーポレーテッド インフルエンザウイルスワクチン
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE102004052026B4 (de) * 2003-11-07 2015-08-27 Totankako Co., Ltd. Kollektor
FR2863758B1 (fr) * 2003-12-11 2006-07-14 Centre Nat Rech Scient Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
BR122018012345B1 (pt) * 2005-04-21 2021-10-26 University Of Florida Research Foundation, Inc. Vetor viral recombinante ou vetor de polinucleotídeo recombinante, e composição
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
CN104826102A (zh) 2006-02-02 2015-08-12 全球免疫股份有限公司 用于诱导免疫应答的基于酵母的疫苗
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions

Also Published As

Publication number Publication date
AP2008004571A0 (en) 2008-08-31
US10335480B2 (en) 2019-07-02
PT1991563E (pt) 2011-12-29
US10765734B2 (en) 2020-09-08
ES2790730T3 (es) 2020-10-29
US20170028053A1 (en) 2017-02-02
ES2374841T3 (es) 2012-02-22
IL251867B (en) 2018-06-28
DK1991563T3 (da) 2012-01-23
CN101395176A (zh) 2009-03-25
EP1991563A2 (en) 2008-11-19
CN102382179A (zh) 2012-03-21
US11439702B2 (en) 2022-09-13
US20230233660A1 (en) 2023-07-27
US20100047275A1 (en) 2010-02-25
CN102807608A (zh) 2012-12-05
US8444995B2 (en) 2013-05-21
KR20080100441A (ko) 2008-11-18
IL251867A0 (en) 2017-06-29
AP2646A (en) 2013-04-17
US20180185470A1 (en) 2018-07-05
EP2383284B1 (en) 2016-08-24
US20190201519A1 (en) 2019-07-04
EA017387B1 (ru) 2012-12-28
US9446116B2 (en) 2016-09-20
GB0613977D0 (en) 2006-08-23
CN102382179B (zh) 2014-01-22
DK3263589T5 (da) 2020-05-25
ATE534660T1 (de) 2011-12-15
WO2007091030A3 (en) 2007-11-08
US8475802B2 (en) 2013-07-02
IL193232A (en) 2017-05-29
CN101395176B (zh) 2013-02-06
PL2383284T3 (pl) 2017-07-31
EP2383285A3 (en) 2012-05-16
PL2383285T3 (pl) 2017-11-30
EP2383285A2 (en) 2011-11-02
CN102807608B (zh) 2015-01-21
EP3263589A3 (en) 2018-02-14
EP3263589A2 (en) 2018-01-03
HK1249115A1 (zh) 2018-10-26
EP2383284A3 (en) 2012-05-30
MX2008010113A (es) 2009-01-19
ES2635590T3 (es) 2017-10-04
CA2641602A1 (en) 2007-08-16
BRPI0707543B8 (pt) 2021-05-25
EP2383284A2 (en) 2011-11-02
US20190365883A1 (en) 2019-12-05
NZ570553A (en) 2012-08-31
BRPI0707543B1 (pt) 2020-11-24
PL3263589T3 (pl) 2020-07-13
PL1991563T3 (pl) 2012-02-29
US20130243804A1 (en) 2013-09-19
US9889191B2 (en) 2018-02-13
US20180147277A1 (en) 2018-05-31
EP3620463A1 (en) 2020-03-11
DK3263589T3 (da) 2020-05-11
EP3320918A2 (en) 2018-05-16
EP1991563B1 (en) 2011-11-23
DK2383285T3 (da) 2017-08-28
SG169392A1 (en) 2011-03-30
JP5603551B2 (ja) 2014-10-08
US10279032B2 (en) 2019-05-07
AU2007213562A2 (en) 2008-11-20
EP2383285B1 (en) 2017-07-12
NO20083416L (no) 2008-11-07
AU2007213562A1 (en) 2007-08-16
EA200870237A1 (ru) 2009-06-30
US20120219575A1 (en) 2012-08-30
US20200397889A1 (en) 2020-12-24
EP3320918A3 (en) 2018-08-01
ES2611034T3 (es) 2017-05-04
JP2009526028A (ja) 2009-07-16
WO2007091030A2 (en) 2007-08-16
IL193232A0 (en) 2009-02-11
EP3263589B1 (en) 2020-03-25
BRPI0707543A2 (pt) 2011-05-03

Similar Documents

Publication Publication Date Title
US11439702B2 (en) Influenza peptides and compositions
EP2004676B1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
AU2013201008C1 (en) Peptide sequences and compositions